Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.64 |
| ▸ | MEN1 | O00255 | 3/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.64 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.63 |
| ▸ | ACACB | O00763 | 4/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 5/20 | 0.50 |
| ▸ | ANPEP | P15144 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | DRD1 | P21728 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20404372 | 0.89 | ACACB (0.64) | MAPTMEN1KMT2AALOX12CTDSP1 | |
| SCHEMBL18398515 | 0.89 | MAPT (0.67) | MAPTMEN1KMT2AALOX12CTDSP1 | |
| SCHEMBL3032550 | 0.87 | MAPT (0.61) | MAPTMEN1KMT2AALOX12CTDSP1 | |
| SCHEMBL20404371 | 0.87 | MAPT (0.61) | MAPTMEN1KMT2AALOX12CTDSP1 | |
| SCHEMBL20409449 | 0.87 | MAPT (0.61) | MAPTMEN1KMT2AALOX12CTDSP1 | |
| SCHEMBL18412176 | 0.87 | MAPT (0.61) | MAPTMEN1KMT2AALOX12CTDSP1 | |
| SCHEMBL18398430 | 0.82 | MAPT (0.56) | MAPTMEN1KMT2AALOX12CTDSP1 | |
| SCHEMBL29044511 | 0.82 | MAPT (0.52) | MAPTMEN1KMT2AALOX12CTDSP1 | |
| SCHEMBL19845885 | 0.81 | NPC1 (0.56) | MAPTMEN1KMT2AALOX12CTDSP1 | |
| SCHEMBL19845884 | 0.81 | MAPT (0.58) | MAPTMEN1KMT2AALOX12CTDSP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118706967-A | Pimulserin tartrate and impurity HPLC detection method | 天津天士力圣特制药有限公司 | 2024-09-27 | — | — | CN | claimed |
| CN-109613163-A | A kind of detection method of tartaric acid Mo Fanselin and its impurity | 丽珠集团新北江制药股份有限公司 | 2019-04-12 | — | — | CN | claimed |
| CN-118706967-A | Pimulserin tartrate and impurity HPLC detection method | 天津天士力圣特制药有限公司 | 2024-09-27 | — | — | CN | disclosed |
| US-11840515-B2 | Methods for preparing N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form c | ACADIA PHARMACEUTICALS INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-11319288-B2 | Method for the preparation of pimavanserin base | OLON S.P.A. (IT) | 2022-05-03 | — | — | US | disclosed |
| EP-3725774-B1 | PROCESS FOR THE PREPARATION OF A PHARMACEUTICAL AGENT | ZAKL FARMACEUTYCZNE POLPHARMA S A (PL) | 2022-02-23 | — | — | EP | disclosed |
| US-20220033356-A1 | PROCESS FOR THE PREPARATION OF PHARMACEUTICAL AGENT | ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. (PL) | 2022-02-03 | — | — | US | disclosed |
| US-20220024871-A1 | METHODS FOR PREPARING N-(4-FLUOROBENZYL)-N-(1-METHYLPIPERIDIN-4-YL)-N'-(4-(2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE AND ITS TARTRATE SALT AND POLYMORPHIC FORM C | ACADIA PHARMACEUTICALS INC. | 2022-01-27 | — | — | US | disclosed |
| EP-3325444-B1 | METHODS FOR PREPARING N-(4-FLUOROBENZYL)-N-(1-METHYLPIPERIDIN-4-YL)-N'-(4-(2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE AND ITS TARTRATE SALT AND POLYMORPHIC FORM C | ACADIA PHARM INC (US) | 2021-07-07 | — | — | EP | disclosed |
| US-20210130296-A1 | METHOD FOR THE PREPARATION OF PIMAVANSERIN BASE | OLON S.P.A. (IT) | 2021-05-06 | — | — | US | disclosed |
| US-10981871-B2 | Methods for preparing N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form C | ACADIA PHARMACEUTICALS INC. (US) | 2021-04-20 | — | — | US | disclosed |
| WO-2017015272-A1 | METHODS FOR PREPARING N-(4-FLUOROBENZYL)-N-(1-METHYLPIPERIDIN-4-YL)-N'-(4-(2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE AND ITS TARTRATE SALT AND POLYMORPHIC FORM C | ACADIA PHARMACEUTICALS INC. (US) | 2017-01-26 | — | — | WO | disclosed |
| US-7790899-B2 | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms | ACADIA PHARMACEUTICALS, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790899-B2 | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms | ACADIA PHARMACEUTICALS, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| WO-2008144326-A2 | SYNTHESIS OF N-(4-FLUOROBENZYL)-N-(L-METHYLPIPERIDIN-4-YL)-N'-(4- (2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE AND ITS TARTRATE SALT AND CRYSTALLINE FORMS | ACADIA PHARMACEUTICALS INC. (US) | 2008-11-27 | — | — | WO | disclosed |
| WO-2007133802-A2 | PHARMACEUTICAL FORMULATIONS OF PIMAVANSERIN | ACADIA PHARMACEUTICALS INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| US-20070264330-A1 | PHARMACEUTICAL FORMULATIONS OF PIMAVANSERIN | ACADIA PHARMACEUTICALS, INC. | 2007-11-15 | — | — | US | disclosed |
| US-20070264330-A1 | PHARMACEUTICAL FORMULATIONS OF PIMAVANSERIN | ACADIA PHARMACEUTICALS, INC. | 2007-11-15 | — | — | US | disclosed |
| US-20070260064-A1 | SYNTHESIS OF N-(4-FLUOROBENZYL)-N-(1-METHYLPIPERIDIN-4-YL)-N'-(4-(2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE AND ITS TARTRATE SALT AND CRYSTALLINE FORMS | ACADIA PHARMACEUTICALS INC. | 2007-11-08 | — | — | US | disclosed |
| US-20070260064-A1 | SYNTHESIS OF N-(4-FLUOROBENZYL)-N-(1-METHYLPIPERIDIN-4-YL)-N'-(4-(2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE AND ITS TARTRATE SALT AND CRYSTALLINE FORMS | ACADIA PHARMACEUTICALS INC. | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070264330-A1 | PHARMACEUTICAL FORMULATIONS OF PIMAVANSERIN | HTR6, HTR5A, HTR7 | MAPT 1367/4885MEN1 3198/4885KMT2A 1799/4885 |
| US-11840515-B2 | Methods for preparing N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form c | NR3C2, NR2C2, CYP4A22 | MAPT 4837/4885MEN1 4247/4885KMT2A 797/4885 |
| US-20070260064-A1 | SYNTHESIS OF N-(4-FLUOROBENZYL)-N-(1-METHYLPIPERIDIN-4-YL)-N'-(4-(2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE AND ITS TARTRATE SALT AND CRYSTALLINE FORMS | MTAP, CPN1, DNPEP | MAPT 1590/4885MEN1 3262/4885KMT2A 913/4885 |
| US-11319288-B2 | Method for the preparation of pimavanserin base | PAH, PIM1, PIM2 | MAPT 2421/4885MEN1 2155/4885KMT2A 163/4885 |
| US-20220024871-A1 | METHODS FOR PREPARING N-(4-FLUOROBENZYL)-N-(1-METHYLPIPERIDIN-4-YL)-N'-(4-(2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE AND ITS TARTRATE SALT AND POLYMORPHIC FORM C | NR3C2, NR2C2, CYP4A22 | MAPT 4837/4885MEN1 4241/4885KMT2A 795/4885 |
| US-20210130296-A1 | METHOD FOR THE PREPARATION OF PIMAVANSERIN BASE | PAH, PIM1, PIM2 | MAPT 2421/4885MEN1 2155/4885KMT2A 163/4885 |
| US-20220033356-A1 | PROCESS FOR THE PREPARATION OF PHARMACEUTICAL AGENT | PIM1, PAH, PIM3 | MAPT 3362/4885MEN1 3219/4885KMT2A 1317/4885 |
| US-10981871-B2 | Methods for preparing N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form C | NR3C2, CYP4A22, NR2C2 | MAPT 4851/4885MEN1 4340/4885KMT2A 983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.